Physician profile
Aurora Lee
NPI 1609597186
$2,395.69
in general payments reported to CMS, 2019-2025
27 companies · $1,425 in 2025
The $1,425 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $332 · 2024: $638 · 2025: $1,425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320 · Education: $75.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.70 |
| Education | $75.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $436.15 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $222.56 | 2025 | |
| Lilly USA, LLC | $180.98 | 2023-2025 | Amyvid, Kisunla |
| Teva Pharmaceuticals USA, INC. | $150.55 | 2024-2025 | Austedo Xr, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $128.82 | 2024-2025 | Ultomiris |
| Viiv Healthcare Company | $122.39 | 2025 | Apretude |
| Vertex Pharmaceuticals Incorporated | $121.83 | 2025 | |
| Ucb, INC. | $103.21 | 2023-2025 | Zilbrysq, Briviact, Rystiggo |
| Novartis Pharmaceuticals Corporation | $100.44 | 2024-2025 | |
| Argenx US, INC. | $78.05 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $75.26 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $75.10 | 2024-2025 | Xeomin, Inbrija |
| Pfizer INC. | $63.45 | 2023-2025 | |
| Genentech USA, INC. | $62.05 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Eisai INC. | $59.04 | 2023-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $57.27 | 2023 | Panzyga |
| Tanabe Pharma America, INC. | $56.50 | 2023-2025 | Radicava |
| Janssen Biotech, INC. | $51.93 | 2025 | Darzalex |
| Amneal Pharmaceuticals LLC | $50.16 | 2025 | Crexont |
| Amgen INC. | $43.10 | 2024-2025 | Uplizna |
| Lundbeck LLC | $34.57 | 2024 | Vyepti |
| Kyowa Kirin, INC. | $27.97 | 2025 | |
| Ge Healthcare | $24.55 | 2024 | |
| Axsome Therapeutics, INC. | $19.29 | 2025 | Symbravo |
| Avion Pharmaceuticals | $19.03 | 2023 | Dhivy |
| Astrazeneca Pharmaceuticals LP | $18.04 | 2024 | Wainua |
| Alnylam Pharmaceuticals INC. | $13.40 | 2024 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurora Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.